Abstract:HomeHypertensionVol. 76, No. 2Does the Mediterranean G6PD S188F Polymorphism Confer Vascular Protection? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBDoes the Mediterranean G6PD S188F Polymorphism Confer Vascular Protection?A Novel Rat Model Offering CRISPR Insight Into High Fat–Induced Vascular Dysfunction and Hypertension Yao Li and Patrick J. Pagano Yao LiYao Li From the Heart, Lung, Blood and Vascular Medicine Institute and Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA. Search for more papers by this author and Patrick J. PaganoPatrick J. Pagano Correspondence to Patrick J. Pagano, Department of Pharmacology and Chemical Biology, University of Pittsburgh, 200 Lothrop St, BST-E1247, Pittsburgh, PA 15261. Email E-mail Address: [email protected] From the Heart, Lung, Blood and Vascular Medicine Institute and Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA. Search for more papers by this author Originally published8 Jul 2020https://doi.org/10.1161/HYPERTENSIONAHA.120.14897Hypertension. 2020;76:314–315This article is a commentary on the followingCRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD VariantSee related article, pp 523–532Glucose-6-phosphate dehydrogenase (G6PD), the first enzyme and rate-limiting step in the pentose phosphate pathway, oxidizes glucose-6-phosphate to 6-phosphogluconolactone, while also serving as a major cell generator of NADPH. As such, G6PD predictably subserves both anti- and pro-oxidant effects in cells.1,2 Via the generation of NADPH, G6PD replenishes reduced glutathione (GSH) from oxidized glutathione (GSSG). It stands to reason then that a polymorphism in G6PD leading to G6PD insufficiency would be expected to increase the GSSG-to-GSH ratio and decrease GSH reductase activity and H2O2 levels.3 eNOS (endothelial NO synthase) and other NOS (NO synthase) isozymes rely on NADPH to convert arginine to citrulline while liberating NO.1 Further, NADPH is the substrate for the Nox (NADPH oxidase) family of enzymes, major sources of reactive oxygen species/reactive nitrogen species in the cardiovascular system4 and myriad other organ systems. Modulation in NADPH levels is expected to cause aberrations in liver metabolic cytochrome P450 and other oxidoreductases that require NADPH as a cofactor. All told, the contribution of G6PD and NADPH is likely to be much more complex than its effects on GSH peroxidase, NOS, and oxidoreductases since an increased oxidation state of a cell or cellular compartment is known to have profound effects on proteins ranging from tyrosine kinases to calcium channels.In this issue, Kitagawa et al5 shed light on our understanding of the impact of G6PD deficiency (one of the most common enzyme deficiencies worldwide) on vascular function and blood pressure. As the authors reveal, the most common complications from G6PD deficiency are neonatal jaundice and hemolytic anemia. However, relevant to the current spotlighted study, the deficiency has been implicated in a higher incidence of hypertension in some cases although the data are not conclusive in that regard.3,6 On the contrary, studies have suggested that the Mediterranean polymorphism is vasoprotective.7–9 Employing CRISPR-Cas9 gene editing, the authors generate a novel rat model replicating a specific human Mediterranean single-nucleotide polymorphism (S188F) that is epidemiologically associated with a lower incidence of vascular disease in humans. With this model, the authors set out to interrogate a potential mechanism afforded by this polymorphism as to whether or not it can be vasculoprotective. Compared with WT (wild type) rats, livers from G6PD mutants display lower G6PD activity by 80%, increased GSSG-to-GSH ratio, and decreased nucleotide levels, all of which rather faithfully recapitulate the human phenotype.10To date, in vitro and in vivo manipulation of G6PD gene expression has yielded mixed results for vascular reactivity. Indeed, G6PD-deficient cells and animals can be more susceptible to oxidative damage and decreased NO levels than WT cells/mice; and animals overexpressing G6PD may be protected against oxidation and generate greater NO.1,3 On the other hand, studies have suggested that hyperlipidemia and hyperglycemia potentiate G6PD activity and NADPH levels leading to augmented superoxide anion production from Nox2 and rat myocardial and vascular dysfunction.11Intriguingly in the current study, the authors’ findings are supportive of a potential reduced propensity for cardiovascular disease in the Mediterranean single-nucleotide polymorphism cohort consistent with clinical data in humans.7–9 Indeed, the high-fat diet representative of metabolic syndrome and applied in the current study is expected to induce vascular abnormalities including vascular dysfunction, inflammation, and vessel stiffening, which all combine to cause greater vasoconstriction and increased blood pressure. However, a lesser increase in systolic and diastolic blood pressure and arterial stiffness was observed in G6PD mutant rats versus WT rats, suggesting that these G6PD-deficient rats are less prone to vascular pathologies elicited by high fat. Moreover, the authors show that the same changes (observed in response to NOS inhibition) in WT rats are markedly attenuated or abrogated in G6PD-deficient rats. As G6PD-derived NADPH is required for NOS-mediated NO production,1 it stands to reason that with lower G6PD activity, mutant rats would have decreased NO synthase activity, and thus application of the NO synthase inhibitor L-NAME (N[ω]-Nitro-L-arginine methyl ester hydrochloride) would yield a lesser response in the G6PD-deficient rats. While the authors conclude that these results are surprising in that they suggest WT arteries are on the whole less functional or healthy than those from mutant rats, the answer may not be that simple. Indeed, at face value, these results might imply that G6PD knockdown, per se, is protective. However, as these rats were deficient since early gestation as global mutants, they may well have developed compensatory protective mechanisms. The findings that WT and G6PD mutant rats have the same baseline blood pressure, arterial stiffness, and acetylcholine-induced relaxation are consistent with that notion.That notwithstanding, with an eye toward deciphering potential protective mechanisms conferred by the G6PD mutation with respect to high fat, the authors proceed to elegantly deconstruct how the vasculature may be protected against the metabolic insult. Toward that end, they present very interesting findings implying that the activity (and not expression) of voltage-gated calcium channels is the culprit—illustrating a higher sensitivity to a selective activator of vascular L-type Ca2+ channels (Bay K8644) in WT compared with G6PD-compromised rats. In more detail, Bay K8644 caused a robust increase in both systolic and diastolic blood pressure in WT rats that was absent in G6PD-deficient rats. Through a series of well-integrated approaches, the authors demonstrate a strikingly lower membrane potential and calcium influx into arterial smooth muscle cells and, in turn, virtual obliteration of KCl-induced vascular constriction and blood pressure rises in the mutants. Hyperpolarization of vascular smooth muscle is proffered as protective in G6PD-deficient rats, which may be attributed to, as the authors proposed, a variety of changes in activities of potassium channels including BKCa and inward rectifier K+ channels, backed up by augmented Kcnmb1 (β-subunit of BKCa) and a suppressed polyamine pathway, respectively.The authors have made several intriguing observations in the G6PD-deficient rats. Still, the current work opens the door to a series of important questions. First and foremost, what redox intermediary, per se, causes the diminished activity of calcium channels and thus vascular reactivity or what mechanistic link connects the measured increase in GSSG and the abovementioned modulators of membrane hyperpolarization? That is, whether changes in peroxide levels cause alterations in calcium channel activity and whether such elevations in peroxides or GSSG bring forth measurable modification in key cysteines on proteins expected to enhance K+ channel activities warrant deeper analysis. Further, as the G6PD mutation is global and extant from the embryonic stage, broad modulation of key proteins and enzyme systems might be brought to bear that are germane to vascular function and hypertension and be corrected with time (to a lesser or greater) degree in the mutant rat versus the human cohort. More to the point, how G6PD deficiency affects superoxide dismutase, catalase, and other enzyme systems in the mutant rats versus human G6PD-deficient cohort might provide greater insight in this regard.Despite these unanswered questions, the current study by Kitagawa et al is conceptually novel, technologically sophisticated, and provides a significant advancement in our understanding of how G6PD and NADPH levels might affect vascular tone and blood pressure under aberrant metabolic conditions. This rat model is expected to provide numerous new mechanistic insights into the manifold ways G6PD activity influences cell signaling in the vasculature and beyond. With G6PD at the nexus of a broad range of essential non–redox-sensitive pathways and redox-sensitive pathways, this new model provides a platform on which wide-ranging inquiries may be made.Sources of FundingThis work is supported by the National Institutes of Health Grants R01HL142248, R01HL079207, R01HL112914, T32GM008424, and AHA 18TPA34170069. This work was also supported by the Institute for Transfusion Medicine, the Hemophilia Center of Western Pennsylvania and the Heart, Lung, Blood and Vascular Medicine Institute of the University of Pittsburgh School of Medicine.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the American Heart Association.Correspondence to Patrick J. Pagano, Department of Pharmacology and Chemical Biology, University of Pittsburgh, 200 Lothrop St, BST-E1247, Pittsburgh, PA 15261. Email [email protected]eduReferences1. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival.IUBMB Life. 2012; 64:362–369. doi: 10.1002/iub.1017CrossrefMedlineGoogle Scholar2. Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, Grüning NM, Krüger A, Tauqeer Alam M, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway.Biol Rev Camb Philos Soc. 2015; 90:927–963. doi: 10.1111/brv.12140CrossrefMedlineGoogle Scholar3. Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease.Am J Physiol Heart Circ Physiol. 2013; 304:H491–H500. doi: 10.1152/ajpheart.00721.2012CrossrefMedlineGoogle Scholar4. Li Y, Pagano PJ. Microvascular NADPH oxidase in health and disease.Free Radic Biol Med. 2017; 109:33–47. doi: 10.1016/j.freeradbiomed.2017.02.049CrossrefMedlineGoogle Scholar5. Kitagawa A, Kizub I, Jacob C, Michael K, D’Alessandro A, Reisz JA, Grzybowski M, Geurts AM, Rocic P, Gupte R, et al. CRISPR-mediated single nucleotide polymorphism modeling in rats reveals insight into reduced cardiovascular risk associated with mediterranean G6PD variant.Hypertension. 2020; 766:523–532. doi: 10.1161/HYPERTENSIONAHA.120.14772LinkGoogle Scholar6. Parsanathan R, Jain SK. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is linked with cardiovascular disease.Hypertens Res. 2020; 43:582–584. doi:10.1038/s41440-020-0402-8CrossrefMedlineGoogle Scholar7. Cocco P, Todde P, Fornera S, Manca MB, Manca P, Sias AR. Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency.Blood. 1998; 91:706–709.CrossrefMedlineGoogle Scholar8. Pinna A, Contini EL, Carru C, Solinas G. Glucose-6-phosphate dehydrogenase deficiency and diabetes mellitus with severe retinal complications in a Sardinian population, Italy.Int J Med Sci. 2013; 10:1907–1913. doi: 10.7150/ijms.6776CrossrefMedlineGoogle Scholar9. Meloni L, Manca MR, Loddo I, Cioglia G, Cocco P, Schwartz A, Muntoni S, Muntoni S. Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease.J Inherit Metab Dis. 2008; 31:412–417. doi: 10.1007/s10545-008-0704-5CrossrefMedlineGoogle Scholar10. Francis RO, Jhang JS, Pham HP, Hod EA, Zimring JC, Spitalnik SL. Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks.Vox Sang. 2013; 105:271–282. doi: 10.1111/vox.12068CrossrefMedlineGoogle Scholar11. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, Recchia F, Stanley W, Wolin MS, Gupte SA. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH.Am J Physiol Heart Circ Physiol. 2009; 297:H153–H162. doi: 10.1152/ajpheart.01142.2008CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD VariantAtsushi Kitagawa, et al. Hypertension. 2020;76:523-532 August 2020Vol 76, Issue 2 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.120.14897PMID: 32639882 Originally publishedJuly 8, 2020 PDF download Advertisement SubjectsCell Signaling/Signal TransductionEndothelium/Vascular Type/Nitric OxideIon Channels/Membrane TransportOxidant StressVascular Biology

Abstract:s are presented in the alphabetical order of the first author names and are printed without editing in the submitted form. The Editorial Office of Physiological Research disclaims any responsibility for errors that may have been made in abstracts submitted by the authors. Proceeding of the 13th International SHR Meeting June 20-22, 2008 Prague, the Czech Republic Vol. 57 Physiol. Res. 2008 37P CLOSING IN ON A MOLECULAR DESCRIPTION OF THE SHR T.J. Aitman MRC Clinical Sciences Centre and Imperial College London, UK Remarkable advances in genomics have occurred in the past 5 years including the advent of whole genome association studies and the ability to re-sequence entire mammalian genomes at a tiny fraction of the cost of the original sequences. The spontaneously hypertensive rat has a distinguished track record as a model of hypertension and metabolic syndrome. Scores of quantitative trait loci (QTLs) have been mapped to discrete regions of the genome over the past two decades and a small number of the underlying molecular defects (quantitative trait nucleotides or QTNs) have been identified. With advances in genome technology and integrative approaches that use expression profiling and informatics, the genome sequence of the SHR is now in our hands, and the opportunity to identify QTNs for large numbers of QTLs presents itself. This talk will address the present state of the art in SHR genomics, and will look to the possibilities for discovery of SHR disease genes and pathways, and their potential translation to human biology, over the next 5 years. PRODUCTION OF GAMMA-AMINOBUTYRIC ACID (GABA)ENRICHED RICE GRAINS AND THEIR HYPOTENSIVE EFFECT BOTH IN SHR/Ncrlcrlj AND SHR/NDmcr-cp/cp K. Akama, J. Kanetou, S. Shimosaki, S. Tsuchikura Department of Biological Science, Shimane University, Matsue, Japan; Department of Experimental Animals, Shimane University, Izumo, Japan; Disease Model Cooperative Research Association, Hamamatsu, Japan Recently, lifestyle-related diseases such as obesity, high blood pressure and hyperlipemia have getting severe problems rest of the world regarding not only human health but also increase in medical expenses. GABA, one of the ubiquitous non-protein amino acids and known to be an inhibitory neurotransmitter, has been focusing due to its effect on blood pressure decrease. GABA itself is synthesized from L-glutamate by glutamate decarboxylase in the cells. Here we report an effect of GABA-enriched rice grains in SHRs. Based upon both molecular approaches of protein engineering and over-expression of a rice GAD gene in the seeds, we have successfully established transgenic rice lines that produce GABA-enriched rice grains: amino acid analysis indicated threeto thirty-fold GABA content increase, compared with those of wild-type. Interestingly, most of the free protein amino acids were also increased in the seeds. GABAenriched rice was administered to ten weeks old of SHR/Ncrlcrlj or eight weeks old of SHR/NDmcr-cp/cp everyday for six weeks (GABA dose of 0.5 mg/kg body weight) and systolic blood pressure was measured. At three, four, and five weeks after administration to two different kinds of SHRs, blood pressure lowering effect was each observed with a statistically significant level compared with the control group. These results suggest that GABA-enriched rice grains developed in this study have a hypotensive effect in SHRs through a long-range action. Transgenic rice grains enriched with free amino acids as well as GABA have a blood pressure lowering effect reproducibly on SHRs. BRAIN DAMAGE IN AN ANIMAL MODEL OF HYPERALDOSTERONISM F. Amenta, D. Tomassoni, B. Toffoli, S. Bernardi, S.K. Tayebati, B. Fabris Department of Experimental Medicine and Public Health, University of Camerino, Camerino, Italy; Department of Clinical Medicine and Neurology, University of Trieste, Trieste, Italy Aldosterone exerts a number of effects in the central nervous system. Facilitated by its lipophilic properties, aldosterone can cross the bloodbrain barrier, and causes acute and long-term effects on brain vascular structures. Aldosterone has been implicated in the pathogenesis of vascular disease and elevated plasma aldosterone is considered as a risk factor for stroke, although mechanism(s) underlying this role remain(s) to be elucidated. The present study was designed to assess possible neuronal, neuroglial and blood-brain-barrier changes induced by aldosterone in an animal model of hyperaldosteronism. Male Wistar rats of 8 weeks of age were treated for 28 days with aldosterone (40 μg/kg/day) via osmotic minipumps with or without 0.9 % NaCl. In control animals, minipumps contained vehicle alone and no salt was added to drinking water. Microanatomical aspects of intracerebral and pial artery, nerve cell number, phosphorylated 200-kDa neurofilament immunoreactivity were assessed by microanatomical, and immunohistochemical techniques. Rats treated with aldosterone alone or plus salt load developed arterial hypertension and displayed microanatomical changes of the vascular tree, nerve cell loss and cytoskeletal breakdown. Neuronal changes occurred primarily in the frontal cortex, striatum and CA1 subfield of hippocampus. These data suggest that aldosterone causes brain injury that can be related with blood pressure rise or with neurotoxicity linked to specific mineralocorticoid receptor activity. Supported by the grant MIUR-COFIN No. 2006060985_003. FUNCTIONAL ANALYSIS OF CARDIOVASCULAR GENES BY TARGETED GENE KNOCKDOWN IN RATS M. Bader Max Delbrück Center for Molecular Medicine (MDC), Berlin-Buch, Germany The rat is the preferred animal model in several areas of research including the study of cardiovascular diseases. However, gene targeting technology is not established for this species due to the lack of germline competent embryonic stem cells. Therefore, our goal was to evaluate different methods to attenuate or ablate expression of a specific gene in transgenic rats. First, we successfully generated a transgenic rat expressing antisense RNA against angiotensinogen exclusively in the brain. These animals showed a 90% reduction in angiotensinogen concentration in the brain with no change in other organs. As a consequence, the rats developed reduced blood pressure, a mild diabetes insipidus and alterations in autonomic control confirming the important function of angiotensin in central cardiovascular control. As a second model we generated transgenic rats expressing a dominant negative mutant of the NPR-B receptor for Ctype natriuretic peptide. These rats spontaneously developed cardiac hypertrophy providing evidence for a central role of this hormone in cardiac growth control. Recently, we used shRNA technology to knockdown genes in rats. We employed a novel tetracycline inducible shRNA expression system targeting the insulin receptor (InsR) and successfully generated shRNA transgenic rats. Doxycycline (DOX) treatment of these animals led to a dose-dependent increase in blood glucose caused by a nearly total inhibition of InsR expression, which was reversible. We could neither detect an interferon response nor any disturbancies in microRNA processing in the transgenic rats under DOX treatment indicating that there are no toxic side effects of the shRNAbased gene suppression. Thus, these rats represent a new model for diabetes mellitus type 2. In conclusion, we have developed novel technologies allowing the specific suppression of genes in the rat. PANEL DISCUSSION: A TRANSGENIC VIEW ON PHYSIOLOGY M. Bader Max-Delbrück-Center for Molecular Medicine, Berlin, Germany When physiologists ask me whether their discipline has a future in the times of -omics, I tell them that it will become even more important. Transgenic researchers such as myself can generate animals with all kinds of alterations in single genes. In a lot of cases the animals survive these handicaps. And then tedious work is necessary to detect the consequences of the genetic alteration, if any. To this purpose, classical 38P Physiol. Res. 2008 Vol. 57 physiology is essential. In particular, system physiology is of greatest importance. Most researchers have a limited focus on a single cell type or organ and analyze their transgenic animal models only with a few established technologies focussing on this tissue. I am sure, hundreds of transgenic lines still bear a secret which would enhance our knowledge about the physiological function of the affected gene. It was not yet uncovered due to an incomplete phenotyping of the animals. Therefore, there are more and more public and commercial labs offering a broad check up of transgenic and knockout mouse lines. And in these labs classical physiology revives. In my lab, we generate animals with alterations in hormone coding genes. If we would not analyze the animals with a multitude of collaboration partners disposing of very divergent expertises in physiology, we would miss the most important phenotypes. For example our mice lacking the enzyme tryptophan hydroxylase 1, which is responsible for serotonin synthesis in the periphery, would have never been comprehensively phenotyped without such partners. We found out that the mice have a defect in hemostasis but our partners discovered functions in the physiology of the mammary gland, the liver, and the pulmonary vasculature. And for sure there are still phenotypes to be discovered in these animals. The most promising and also most important in the respect of this meeting is that the mice are slightly hypertensive. Thus surprisingly, peripheral serotonin exerts a tonic antihypertensive effect. By employing classical systems physiology of cardiovascular regulation we try to clarify the implicated mechanisms in the moment. In conclusion, classical physiology will not die out. In the opposite, it becomes an increasingly indispensable tool in the analysis of genetically altered animal models. CHRONIC CROWDING STRESS PRODUCES NITRIC OXIDE DEFICIENCY AND EN

Does the Mediterranean G6PD S188F Polymorphism Confer Vascular Protection?

CRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD Variant

Novel Humanized G6PD Deficient Mice Reveal Mechanisms of Increased Tolerance to Exercise As Gleaned By Multi-Omics in Models of Critical Speed

G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease

Protective Protein/Cathepsin A Loss in Cultured Cells Derived from an Early-Infantile Form of Galactosialidosis Patients Homozygous for the A1184-G Transition (y395c Mutation)

Glucose-6-Phosphate Dehydrogenase Deficiency Activates Endothelial Cell and Leukocyte Adhesion Mediated via the TGFβ/NADPH Oxidases/ROS Signaling Pathway

Increased exercise tolerance in humanized G6PD deficient mice

Glucose-6-phosphate dehydrogenase exerts antistress effects independently of its enzymatic activity

Functional effects of an African glucose‐6‐phosphate dehydrogenase (G6PD) polymorphism (Val68Met) on red blood cell hemolytic propensity and post‐transfusion recovery

Glucose 6-P Dehydrogenase-An Antioxidant Enzyme with Regulatory Functions in Skeletal Muscle during Exercise

Hematologic and systemic metabolic alterations due to Mediterranean class II G6PD deficiency in mice

Functional Analysis of G6PD Variants Associated With Low G6PD Activity in the All of Us Research Program

Hypoxic Activation of G6PD Controls the Expression of Genes Involved in the Pathogenesis of Pulmonary Hypertension Through the Regulation of DNA Methylation.

G6PD maintains the VSMC synthetic phenotype and accelerates vascular neointimal hyperplasia by inhibiting the VDAC1–Bax-mediated mitochondrial apoptosis pathway

Evaluation of the Functional Effects of an African American Glucose-6-Phosphate Dehydrogenase (G6PD) Polymorphism (Val68Met) on RBC Hemolytic Propensity and Post-Transfusion Recovery in a Humanized Mouse Model

Substitution of arginine 219 by glycine compromises stability, dimerization, and catalytic activity in a G6PD mutant

Regulation of G6PD Acetylation by SIRT2 and KAT9 Modulates NADPH Homeostasis and Cell Survival During Oxidative Stress

Proceeding of the 13th International SHR Meeting

Abstract 13610: Imbalance Between GCN5L1 Mediated CypD Acetylation and Sirt3 Deacetylase Promotes Mitochondrial Oxidative Stress, Endothelial Dysfunction and Hypertension

Stabilization of glucose-6-phosphate dehydrogenase oligomers enhances catalytic activity and stability of clinical variants

Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis.